🔗 Share this article

As the United States proceeds with unprecedented adjustments to its vaccination guidelines, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid shots during the global health crisis and has zeroed in on possible fatalities after Covid vaccination in her recent time at the FDA.

Scheduled Overhauls to Childhood Vaccine Schedule

Public health authorities planned to reveal radical revisions to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, it is understood – a significant shift that would place the US out of step with a large portion of the international standard with no evidence for public health gain. The planned update has been pushed back until the coming year.

Instead of Vinay Prasad, Dr. Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for ending specific pediatric vaccine recommendations in the US so as to align more similar to the Danish model, a nation with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

So far comments, she has continued to focus on vaccines – usually the responsibility of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, oversight or leadership, which has been standard for former directors of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Past heads of the center would “grasp legal statutes and the research of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

CDER has an vast portfolio at the agency, she pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars division, OTC medication office and so forth, and all of those must be supervised,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a substantial administrative element to the job, which supervises more than 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” she added.

Official Statement and Contentious Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this appointment represents greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “inquiries stem from flawed assumptions”.

“Her resume is consistent with the responsibilities of her position,” the official said, citing the period Dr. Høeg spent advising the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a disputed one-day medication authorization process that allegedly concerned her predecessors. “By what process are these medications being picked for this voucher program? Who makes the calls?” Dr. Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards more relaxed rules of most medications, aside from immunizations.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if concerning, past, Howard said. She published a analysis using unconfirmed crowd-sourced reports to determine the frequency of myocarditis following Covid vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership included changing rules for new vaccines and halting “optional” vaccines, she remarked post-election on a online show. At the agency, Dr. Høeg has reportedly suggested preventing young men from receiving COVID-19 vaccinations.

“She is an thorough true believer who starts off with her beliefs and works backwards to retrofit the data in a very disingenuous, fraudulent fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|